Combination	O
of	O
a	O
STAT3	B:C0253050
Inhibitor	O
and	O
an	O
mTOR	O
Inhibitor	I:C2746052
Against	O
a	O
Temozolomide	O
-	O
resistant	O
Glioblastoma	O
Cell	O
Line	I:C0007634
Temozolomide	O
-	O
resistant	O
(	O
TMZ	O
-	O
R	O
)	O
glioblastoma	O
is	O
very	O
difficult	O
to	O
treat	O
,	O
and	O
a	O
novel	O
approach	O
to	O
overcome	O
resistance	O
is	O
needed	O
.	O

Combination	O
of	O
a	O
STAT3	O
Inhibitor	B:C0243077
and	O
an	O
mTOR	O
Inhibitor	I:C2746052
Against	O
a	O
Temozolomide	O
-	O
resistant	O
Glioblastoma	O
Cell	O
Line	I:C0007634
Temozolomide	O
-	O
resistant	O
(	O
TMZ	O
-	O
R	O
)	O
glioblastoma	O
is	O
very	O
difficult	O
to	O
treat	O
,	O
and	O
a	O
novel	O
approach	O
to	O
overcome	O
resistance	O
is	O
needed	O
.	O

Combination	O
of	O
a	O
STAT3	O
Inhibitor	O
and	O
an	O
mTOR	B:C2746052
Inhibitor	I:C2746052
Against	O
a	O
Temozolomide	O
-	O
resistant	O
Glioblastoma	O
Cell	O
Line	I:C0007634
Temozolomide	O
-	O
resistant	O
(	O
TMZ	O
-	O
R	O
)	O
glioblastoma	O
is	O
very	O
difficult	O
to	O
treat	O
,	O
and	O
a	O
novel	O
approach	O
to	O
overcome	O
resistance	O
is	O
needed	O
.	O

Combination	O
of	O
a	O
STAT3	O
Inhibitor	O
and	O
an	O
mTOR	O
Inhibitor	I:C2746052
Against	O
a	O
Temozolomide	B:C0076080
-	O
resistant	O
Glioblastoma	O
Cell	O
Line	I:C0007634
Temozolomide	O
-	O
resistant	O
(	O
TMZ	O
-	O
R	O
)	O
glioblastoma	O
is	O
very	O
difficult	O
to	O
treat	O
,	O
and	O
a	O
novel	O
approach	O
to	O
overcome	O
resistance	O
is	O
needed	O
.	O

Combination	O
of	O
a	O
STAT3	O
Inhibitor	O
and	O
an	O
mTOR	O
Inhibitor	I:C2746052
Against	O
a	O
Temozolomide	O
-	O
resistant	B:C0013203
Glioblastoma	O
Cell	O
Line	I:C0007634
Temozolomide	O
-	O
resistant	O
(	O
TMZ	O
-	O
R	O
)	O
glioblastoma	O
is	O
very	O
difficult	O
to	O
treat	O
,	O
and	O
a	O
novel	O
approach	O
to	O
overcome	O
resistance	O
is	O
needed	O
.	O

Combination	O
of	O
a	O
STAT3	O
Inhibitor	O
and	O
an	O
mTOR	O
Inhibitor	I:C2746052
Against	O
a	O
Temozolomide	O
-	O
resistant	O
Glioblastoma	B:C0017636
Cell	O
Line	I:C0007634
Temozolomide	O
-	O
resistant	O
(	O
TMZ	O
-	O
R	O
)	O
glioblastoma	O
is	O
very	O
difficult	O
to	O
treat	O
,	O
and	O
a	O
novel	O
approach	O
to	O
overcome	O
resistance	O
is	O
needed	O
.	O

Combination	O
of	O
a	O
STAT3	O
Inhibitor	O
and	O
an	O
mTOR	O
Inhibitor	I:C2746052
Against	O
a	O
Temozolomide	O
-	O
resistant	O
Glioblastoma	O
Cell	B:C0007634
Line	I:C0007634
Temozolomide	O
-	O
resistant	O
(	O
TMZ	O
-	O
R	O
)	O
glioblastoma	O
is	O
very	O
difficult	O
to	O
treat	O
,	O
and	O
a	O
novel	O
approach	O
to	O
overcome	O
resistance	O
is	O
needed	O
.	O

Combination	O
of	O
a	O
STAT3	O
Inhibitor	O
and	O
an	O
mTOR	O
Inhibitor	I:C2746052
Against	O
a	O
Temozolomide	O
-	O
resistant	O
Glioblastoma	O
Cell	O
Line	I:C0007634
Temozolomide	B:C0076080
-	O
resistant	O
(	O
TMZ	O
-	O
R	O
)	O
glioblastoma	O
is	O
very	O
difficult	O
to	O
treat	O
,	O
and	O
a	O
novel	O
approach	O
to	O
overcome	O
resistance	O
is	O
needed	O
.	O

Combination	O
of	O
a	O
STAT3	O
Inhibitor	O
and	O
an	O
mTOR	O
Inhibitor	I:C2746052
Against	O
a	O
Temozolomide	O
-	O
resistant	O
Glioblastoma	O
Cell	O
Line	I:C0007634
Temozolomide	O
-	O
resistant	B:C0013203
(	O
TMZ	O
-	O
R	O
)	O
glioblastoma	O
is	O
very	O
difficult	O
to	O
treat	O
,	O
and	O
a	O
novel	O
approach	O
to	O
overcome	O
resistance	O
is	O
needed	O
.	O

Combination	O
of	O
a	O
STAT3	O
Inhibitor	O
and	O
an	O
mTOR	O
Inhibitor	I:C2746052
Against	O
a	O
Temozolomide	O
-	O
resistant	O
Glioblastoma	O
Cell	O
Line	I:C0007634
Temozolomide	O
-	O
resistant	O
(	O
TMZ	B:C0076080
-	O
R	O
)	O
glioblastoma	O
is	O
very	O
difficult	O
to	O
treat	O
,	O
and	O
a	O
novel	O
approach	O
to	O
overcome	O
resistance	O
is	O
needed	O
.	O

Combination	O
of	O
a	O
STAT3	O
Inhibitor	O
and	O
an	O
mTOR	O
Inhibitor	I:C2746052
Against	O
a	O
Temozolomide	O
-	O
resistant	O
Glioblastoma	O
Cell	O
Line	I:C0007634
Temozolomide	O
-	O
resistant	O
(	O
TMZ	O
-	O
R	B:C0013203
)	O
glioblastoma	O
is	O
very	O
difficult	O
to	O
treat	O
,	O
and	O
a	O
novel	O
approach	O
to	O
overcome	O
resistance	O
is	O
needed	O
.	O

Combination	O
of	O
a	O
STAT3	O
Inhibitor	O
and	O
an	O
mTOR	O
Inhibitor	I:C2746052
Against	O
a	O
Temozolomide	O
-	O
resistant	O
Glioblastoma	O
Cell	O
Line	I:C0007634
Temozolomide	O
-	O
resistant	O
(	O
TMZ	O
-	O
R	O
)	O
glioblastoma	B:C0017636
is	O
very	O
difficult	O
to	O
treat	O
,	O
and	O
a	O
novel	O
approach	O
to	O
overcome	O
resistance	O
is	O
needed	O
.	O

Combination	O
of	O
a	O
STAT3	O
Inhibitor	O
and	O
an	O
mTOR	O
Inhibitor	I:C2746052
Against	O
a	O
Temozolomide	O
-	O
resistant	O
Glioblastoma	O
Cell	O
Line	I:C0007634
Temozolomide	O
-	O
resistant	O
(	O
TMZ	O
-	O
R	O
)	O
glioblastoma	O
is	O
very	O
difficult	O
to	O
treat	B:C0087111
,	O
and	O
a	O
novel	O
approach	O
to	O
overcome	O
resistance	O
is	O
needed	O
.	O

Combination	O
of	O
a	O
STAT3	O
Inhibitor	O
and	O
an	O
mTOR	O
Inhibitor	I:C2746052
Against	O
a	O
Temozolomide	O
-	O
resistant	O
Glioblastoma	O
Cell	O
Line	I:C0007634
Temozolomide	O
-	O
resistant	O
(	O
TMZ	O
-	O
R	O
)	O
glioblastoma	O
is	O
very	O
difficult	O
to	O
treat	O
,	O
and	O
a	O
novel	O
approach	O
to	O
overcome	O
resistance	B:C0013203
is	O
needed	O
.	O

The	O
efficacy	O
of	O
a	O
combination	O
treatment	B:C0087111
of	O
STAT3	O
inhibitor	O
,	O
STX	O
-	I:C3177942
0119	I:C3177942
,	O
with	O
rapamycin	O
was	O
investigated	O
against	O
our	O
established	O
TMZ	O
-	O
resistant	O
U87	O
cell	I:C0007634
line	I:C0007634
.	O

The	O
efficacy	O
of	O
a	O
combination	O
treatment	O
of	O
STAT3	B:C0253050
inhibitor	O
,	O
STX	O
-	I:C3177942
0119	I:C3177942
,	O
with	O
rapamycin	O
was	O
investigated	O
against	O
our	O
established	O
TMZ	O
-	O
resistant	O
U87	O
cell	I:C0007634
line	I:C0007634
.	O

The	O
efficacy	O
of	O
a	O
combination	O
treatment	O
of	O
STAT3	O
inhibitor	B:C0243077
,	O
STX	O
-	I:C3177942
0119	I:C3177942
,	O
with	O
rapamycin	O
was	O
investigated	O
against	O
our	O
established	O
TMZ	O
-	O
resistant	O
U87	O
cell	I:C0007634
line	I:C0007634
.	O

The	O
efficacy	O
of	O
a	O
combination	O
treatment	O
of	O
STAT3	O
inhibitor	O
,	O
STX	B:C3177942
-	I:C3177942
0119	I:C3177942
,	O
with	O
rapamycin	O
was	O
investigated	O
against	O
our	O
established	O
TMZ	O
-	O
resistant	O
U87	O
cell	I:C0007634
line	I:C0007634
.	O

The	O
efficacy	O
of	O
a	O
combination	O
treatment	O
of	O
STAT3	O
inhibitor	O
,	O
STX	O
-	I:C3177942
0119	I:C3177942
,	O
with	O
rapamycin	B:C0072980
was	O
investigated	O
against	O
our	O
established	O
TMZ	O
-	O
resistant	O
U87	O
cell	I:C0007634
line	I:C0007634
.	O

The	O
efficacy	O
of	O
a	O
combination	O
treatment	O
of	O
STAT3	O
inhibitor	O
,	O
STX	O
-	I:C3177942
0119	I:C3177942
,	O
with	O
rapamycin	O
was	O
investigated	O
against	O
our	O
established	O
TMZ	B:C0076080
-	O
resistant	O
U87	O
cell	I:C0007634
line	I:C0007634
.	O

The	O
efficacy	O
of	O
a	O
combination	O
treatment	O
of	O
STAT3	O
inhibitor	O
,	O
STX	O
-	I:C3177942
0119	I:C3177942
,	O
with	O
rapamycin	O
was	O
investigated	O
against	O
our	O
established	O
TMZ	O
-	O
resistant	B:C0013203
U87	O
cell	I:C0007634
line	I:C0007634
.	O

The	O
efficacy	O
of	O
a	O
combination	O
treatment	O
of	O
STAT3	O
inhibitor	O
,	O
STX	O
-	I:C3177942
0119	I:C3177942
,	O
with	O
rapamycin	O
was	O
investigated	O
against	O
our	O
established	O
TMZ	O
-	O
resistant	O
U87	B:C0007634
cell	I:C0007634
line	I:C0007634
.	O

The	O
growth	B:C0007613
-	I:C0007613
inhibitory	I:C0007613
effect	I:C0007613
of	O
the	O
combination	O
treatment	O
was	O
significant	O
against	O
the	O
TMZ	O
-	O
R	O
U87	O
cell	I:C0007634
line	I:C0007634
(	O
IC50	O
:	O
78	O
μM	O
for	O
STX	O
-	I:C3177942
0119	I:C3177942
,	O
30.5	O
μM	O
for	O
rapamycin	O
and	O
11.3	O
μM	O
for	O
combination	O
of	O
the	O
two	O
)	O
.	O

The	O
growth	O
-	I:C0007613
inhibitory	I:C0007613
effect	I:C0007613
of	O
the	O
combination	O
treatment	B:C0087111
was	O
significant	O
against	O
the	O
TMZ	O
-	O
R	O
U87	O
cell	I:C0007634
line	I:C0007634
(	O
IC50	O
:	O
78	O
μM	O
for	O
STX	O
-	I:C3177942
0119	I:C3177942
,	O
30.5	O
μM	O
for	O
rapamycin	O
and	O
11.3	O
μM	O
for	O
combination	O
of	O
the	O
two	O
)	O
.	O

The	O
growth	O
-	I:C0007613
inhibitory	I:C0007613
effect	I:C0007613
of	O
the	O
combination	O
treatment	O
was	O
significant	O
against	O
the	O
TMZ	B:C0076080
-	O
R	O
U87	O
cell	I:C0007634
line	I:C0007634
(	O
IC50	O
:	O
78	O
μM	O
for	O
STX	O
-	I:C3177942
0119	I:C3177942
,	O
30.5	O
μM	O
for	O
rapamycin	O
and	O
11.3	O
μM	O
for	O
combination	O
of	O
the	O
two	O
)	O
.	O

The	O
growth	O
-	I:C0007613
inhibitory	I:C0007613
effect	I:C0007613
of	O
the	O
combination	O
treatment	O
was	O
significant	O
against	O
the	O
TMZ	O
-	O
R	B:C0013203
U87	O
cell	I:C0007634
line	I:C0007634
(	O
IC50	O
:	O
78	O
μM	O
for	O
STX	O
-	I:C3177942
0119	I:C3177942
,	O
30.5	O
μM	O
for	O
rapamycin	O
and	O
11.3	O
μM	O
for	O
combination	O
of	O
the	O
two	O
)	O
.	O

The	O
growth	O
-	I:C0007613
inhibitory	I:C0007613
effect	I:C0007613
of	O
the	O
combination	O
treatment	O
was	O
significant	O
against	O
the	O
TMZ	O
-	O
R	O
U87	B:C0007634
cell	I:C0007634
line	I:C0007634
(	O
IC50	O
:	O
78	O
μM	O
for	O
STX	O
-	I:C3177942
0119	I:C3177942
,	O
30.5	O
μM	O
for	O
rapamycin	O
and	O
11.3	O
μM	O
for	O
combination	O
of	O
the	O
two	O
)	O
.	O

The	O
growth	O
-	I:C0007613
inhibitory	I:C0007613
effect	I:C0007613
of	O
the	O
combination	O
treatment	O
was	O
significant	O
against	O
the	O
TMZ	O
-	O
R	O
U87	O
cell	I:C0007634
line	I:C0007634
(	O
IC50	O
:	O
78	O
μM	O
for	O
STX	B:C3177942
-	I:C3177942
0119	I:C3177942
,	O
30.5	O
μM	O
for	O
rapamycin	O
and	O
11.3	O
μM	O
for	O
combination	O
of	O
the	O
two	O
)	O
.	O

The	O
growth	O
-	I:C0007613
inhibitory	I:C0007613
effect	I:C0007613
of	O
the	O
combination	O
treatment	O
was	O
significant	O
against	O
the	O
TMZ	O
-	O
R	O
U87	O
cell	I:C0007634
line	I:C0007634
(	O
IC50	O
:	O
78	O
μM	O
for	O
STX	O
-	I:C3177942
0119	I:C3177942
,	O
30.5	O
μM	O
for	O
rapamycin	B:C0072980
and	O
11.3	O
μM	O
for	O
combination	O
of	O
the	O
two	O
)	O
.	O

Western	B:C0005863
blotting	I:C0005863
analysis	I:C0005863
demonstrated	O
that	O
the	O
inhibitory	O
effect	I:C0007613
of	O
STX	O
-	I:C3177942
0119	I:C3177942
on	O
S6	O
and	O
4E	O
-	I:C0254260
BP1	I:C0254260
activation	O
through	O
regulation	O
of	O
YKL	O
-	I:C0528649
40	I:C0528649
expression	O
occurred	O
in	O
addition	O
to	O
the	O
inhibitory	O
effect	I:C0007613
of	O
rapamycin	O
against	O
the	O
mTOR	O
pathway	I:C1515673
.	O

Western	O
blotting	I:C0005863
analysis	I:C0005863
demonstrated	O
that	O
the	O
inhibitory	B:C0007613
effect	I:C0007613
of	O
STX	O
-	I:C3177942
0119	I:C3177942
on	O
S6	O
and	O
4E	O
-	I:C0254260
BP1	I:C0254260
activation	O
through	O
regulation	O
of	O
YKL	O
-	I:C0528649
40	I:C0528649
expression	O
occurred	O
in	O
addition	O
to	O
the	O
inhibitory	O
effect	I:C0007613
of	O
rapamycin	O
against	O
the	O
mTOR	O
pathway	I:C1515673
.	O

Western	O
blotting	I:C0005863
analysis	I:C0005863
demonstrated	O
that	O
the	O
inhibitory	O
effect	I:C0007613
of	O
STX	B:C3177942
-	I:C3177942
0119	I:C3177942
on	O
S6	O
and	O
4E	O
-	I:C0254260
BP1	I:C0254260
activation	O
through	O
regulation	O
of	O
YKL	O
-	I:C0528649
40	I:C0528649
expression	O
occurred	O
in	O
addition	O
to	O
the	O
inhibitory	O
effect	I:C0007613
of	O
rapamycin	O
against	O
the	O
mTOR	O
pathway	I:C1515673
.	O

Western	O
blotting	I:C0005863
analysis	I:C0005863
demonstrated	O
that	O
the	O
inhibitory	O
effect	I:C0007613
of	O
STX	O
-	I:C3177942
0119	I:C3177942
on	O
S6	B:C0073337
and	O
4E	O
-	I:C0254260
BP1	I:C0254260
activation	O
through	O
regulation	O
of	O
YKL	O
-	I:C0528649
40	I:C0528649
expression	O
occurred	O
in	O
addition	O
to	O
the	O
inhibitory	O
effect	I:C0007613
of	O
rapamycin	O
against	O
the	O
mTOR	O
pathway	I:C1515673
.	O

Western	O
blotting	I:C0005863
analysis	I:C0005863
demonstrated	O
that	O
the	O
inhibitory	O
effect	I:C0007613
of	O
STX	O
-	I:C3177942
0119	I:C3177942
on	O
S6	O
and	O
4E	B:C0254260
-	I:C0254260
BP1	I:C0254260
activation	O
through	O
regulation	O
of	O
YKL	O
-	I:C0528649
40	I:C0528649
expression	O
occurred	O
in	O
addition	O
to	O
the	O
inhibitory	O
effect	I:C0007613
of	O
rapamycin	O
against	O
the	O
mTOR	O
pathway	I:C1515673
.	O

Western	O
blotting	I:C0005863
analysis	I:C0005863
demonstrated	O
that	O
the	O
inhibitory	O
effect	I:C0007613
of	O
STX	O
-	I:C3177942
0119	I:C3177942
on	O
S6	O
and	O
4E	O
-	I:C0254260
BP1	I:C0254260
activation	B:C0014429
through	O
regulation	O
of	O
YKL	O
-	I:C0528649
40	I:C0528649
expression	O
occurred	O
in	O
addition	O
to	O
the	O
inhibitory	O
effect	I:C0007613
of	O
rapamycin	O
against	O
the	O
mTOR	O
pathway	I:C1515673
.	O

Western	O
blotting	I:C0005863
analysis	I:C0005863
demonstrated	O
that	O
the	O
inhibitory	O
effect	I:C0007613
of	O
STX	O
-	I:C3177942
0119	I:C3177942
on	O
S6	O
and	O
4E	O
-	I:C0254260
BP1	I:C0254260
activation	O
through	O
regulation	B:C0017263
of	O
YKL	O
-	I:C0528649
40	I:C0528649
expression	O
occurred	O
in	O
addition	O
to	O
the	O
inhibitory	O
effect	I:C0007613
of	O
rapamycin	O
against	O
the	O
mTOR	O
pathway	I:C1515673
.	O

Western	O
blotting	I:C0005863
analysis	I:C0005863
demonstrated	O
that	O
the	O
inhibitory	O
effect	I:C0007613
of	O
STX	O
-	I:C3177942
0119	I:C3177942
on	O
S6	O
and	O
4E	O
-	I:C0254260
BP1	I:C0254260
activation	O
through	O
regulation	O
of	O
YKL	B:C0528649
-	I:C0528649
40	I:C0528649
expression	O
occurred	O
in	O
addition	O
to	O
the	O
inhibitory	O
effect	I:C0007613
of	O
rapamycin	O
against	O
the	O
mTOR	O
pathway	I:C1515673
.	O

Western	O
blotting	I:C0005863
analysis	I:C0005863
demonstrated	O
that	O
the	O
inhibitory	O
effect	I:C0007613
of	O
STX	O
-	I:C3177942
0119	I:C3177942
on	O
S6	O
and	O
4E	O
-	I:C0254260
BP1	I:C0254260
activation	O
through	O
regulation	O
of	O
YKL	O
-	I:C0528649
40	I:C0528649
expression	B:C1171362
occurred	O
in	O
addition	O
to	O
the	O
inhibitory	O
effect	I:C0007613
of	O
rapamycin	O
against	O
the	O
mTOR	O
pathway	I:C1515673
.	O

Western	O
blotting	I:C0005863
analysis	I:C0005863
demonstrated	O
that	O
the	O
inhibitory	O
effect	I:C0007613
of	O
STX	O
-	I:C3177942
0119	I:C3177942
on	O
S6	O
and	O
4E	O
-	I:C0254260
BP1	I:C0254260
activation	O
through	O
regulation	O
of	O
YKL	O
-	I:C0528649
40	I:C0528649
expression	O
occurred	O
in	O
addition	O
to	O
the	O
inhibitory	B:C0007613
effect	I:C0007613
of	O
rapamycin	O
against	O
the	O
mTOR	O
pathway	I:C1515673
.	O

Western	O
blotting	I:C0005863
analysis	I:C0005863
demonstrated	O
that	O
the	O
inhibitory	O
effect	I:C0007613
of	O
STX	O
-	I:C3177942
0119	I:C3177942
on	O
S6	O
and	O
4E	O
-	I:C0254260
BP1	I:C0254260
activation	O
through	O
regulation	O
of	O
YKL	O
-	I:C0528649
40	I:C0528649
expression	O
occurred	O
in	O
addition	O
to	O
the	O
inhibitory	O
effect	I:C0007613
of	O
rapamycin	B:C0072980
against	O
the	O
mTOR	O
pathway	I:C1515673
.	O

Western	O
blotting	I:C0005863
analysis	I:C0005863
demonstrated	O
that	O
the	O
inhibitory	O
effect	I:C0007613
of	O
STX	O
-	I:C3177942
0119	I:C3177942
on	O
S6	O
and	O
4E	O
-	I:C0254260
BP1	I:C0254260
activation	O
through	O
regulation	O
of	O
YKL	O
-	I:C0528649
40	I:C0528649
expression	O
occurred	O
in	O
addition	O
to	O
the	O
inhibitory	O
effect	I:C0007613
of	O
rapamycin	O
against	O
the	O
mTOR	B:C1515673
pathway	I:C1515673
.	O

These	O
results	O
suggest	O
that	O
the	O
STAT3	B:C0253050
pathway	O
is	O
associated	O
with	O
the	O
mTOR	O
downstream	I:C1515673
pathway	I:C1515673
mediated	O
by	O
YKL	O
-	I:C0528649
40	I:C0528649
protein	I:C0528649
,	O
and	O
the	O
combination	O
therapy	O
of	O
the	O
STAT3	O
inhibitor	O
and	O
rapamycin	O
could	O
be	O
worth	O
developing	O
as	O
a	O
novel	O
therapeutic	O
approach	I:C0087111
against	O
TMZ	O
-	O
resistant	O
relapsed	O
gliomas	O
.	O

These	O
results	O
suggest	O
that	O
the	O
STAT3	O
pathway	B:C1704259
is	O
associated	O
with	O
the	O
mTOR	O
downstream	I:C1515673
pathway	I:C1515673
mediated	O
by	O
YKL	O
-	I:C0528649
40	I:C0528649
protein	I:C0528649
,	O
and	O
the	O
combination	O
therapy	O
of	O
the	O
STAT3	O
inhibitor	O
and	O
rapamycin	O
could	O
be	O
worth	O
developing	O
as	O
a	O
novel	O
therapeutic	O
approach	I:C0087111
against	O
TMZ	O
-	O
resistant	O
relapsed	O
gliomas	O
.	O

These	O
results	O
suggest	O
that	O
the	O
STAT3	O
pathway	O
is	O
associated	O
with	O
the	O
mTOR	B:C1515673
downstream	I:C1515673
pathway	I:C1515673
mediated	O
by	O
YKL	O
-	I:C0528649
40	I:C0528649
protein	I:C0528649
,	O
and	O
the	O
combination	O
therapy	O
of	O
the	O
STAT3	O
inhibitor	O
and	O
rapamycin	O
could	O
be	O
worth	O
developing	O
as	O
a	O
novel	O
therapeutic	O
approach	I:C0087111
against	O
TMZ	O
-	O
resistant	O
relapsed	O
gliomas	O
.	O

These	O
results	O
suggest	O
that	O
the	O
STAT3	O
pathway	O
is	O
associated	O
with	O
the	O
mTOR	O
downstream	I:C1515673
pathway	I:C1515673
mediated	O
by	O
YKL	B:C0528649
-	I:C0528649
40	I:C0528649
protein	I:C0528649
,	O
and	O
the	O
combination	O
therapy	O
of	O
the	O
STAT3	O
inhibitor	O
and	O
rapamycin	O
could	O
be	O
worth	O
developing	O
as	O
a	O
novel	O
therapeutic	O
approach	I:C0087111
against	O
TMZ	O
-	O
resistant	O
relapsed	O
gliomas	O
.	O

These	O
results	O
suggest	O
that	O
the	O
STAT3	O
pathway	O
is	O
associated	O
with	O
the	O
mTOR	O
downstream	I:C1515673
pathway	I:C1515673
mediated	O
by	O
YKL	O
-	I:C0528649
40	I:C0528649
protein	I:C0528649
,	O
and	O
the	O
combination	O
therapy	B:C0087111
of	O
the	O
STAT3	O
inhibitor	O
and	O
rapamycin	O
could	O
be	O
worth	O
developing	O
as	O
a	O
novel	O
therapeutic	O
approach	I:C0087111
against	O
TMZ	O
-	O
resistant	O
relapsed	O
gliomas	O
.	O

These	O
results	O
suggest	O
that	O
the	O
STAT3	O
pathway	O
is	O
associated	O
with	O
the	O
mTOR	O
downstream	I:C1515673
pathway	I:C1515673
mediated	O
by	O
YKL	O
-	I:C0528649
40	I:C0528649
protein	I:C0528649
,	O
and	O
the	O
combination	O
therapy	O
of	O
the	O
STAT3	B:C0253050
inhibitor	O
and	O
rapamycin	O
could	O
be	O
worth	O
developing	O
as	O
a	O
novel	O
therapeutic	O
approach	I:C0087111
against	O
TMZ	O
-	O
resistant	O
relapsed	O
gliomas	O
.	O

These	O
results	O
suggest	O
that	O
the	O
STAT3	O
pathway	O
is	O
associated	O
with	O
the	O
mTOR	O
downstream	I:C1515673
pathway	I:C1515673
mediated	O
by	O
YKL	O
-	I:C0528649
40	I:C0528649
protein	I:C0528649
,	O
and	O
the	O
combination	O
therapy	O
of	O
the	O
STAT3	O
inhibitor	B:C0243077
and	O
rapamycin	O
could	O
be	O
worth	O
developing	O
as	O
a	O
novel	O
therapeutic	O
approach	I:C0087111
against	O
TMZ	O
-	O
resistant	O
relapsed	O
gliomas	O
.	O

These	O
results	O
suggest	O
that	O
the	O
STAT3	O
pathway	O
is	O
associated	O
with	O
the	O
mTOR	O
downstream	I:C1515673
pathway	I:C1515673
mediated	O
by	O
YKL	O
-	I:C0528649
40	I:C0528649
protein	I:C0528649
,	O
and	O
the	O
combination	O
therapy	O
of	O
the	O
STAT3	O
inhibitor	O
and	O
rapamycin	B:C0072980
could	O
be	O
worth	O
developing	O
as	O
a	O
novel	O
therapeutic	O
approach	I:C0087111
against	O
TMZ	O
-	O
resistant	O
relapsed	O
gliomas	O
.	O

These	O
results	O
suggest	O
that	O
the	O
STAT3	O
pathway	O
is	O
associated	O
with	O
the	O
mTOR	O
downstream	I:C1515673
pathway	I:C1515673
mediated	O
by	O
YKL	O
-	I:C0528649
40	I:C0528649
protein	I:C0528649
,	O
and	O
the	O
combination	O
therapy	O
of	O
the	O
STAT3	O
inhibitor	O
and	O
rapamycin	O
could	O
be	O
worth	O
developing	O
as	O
a	O
novel	O
therapeutic	B:C0087111
approach	I:C0087111
against	O
TMZ	O
-	O
resistant	O
relapsed	O
gliomas	O
.	O

These	O
results	O
suggest	O
that	O
the	O
STAT3	O
pathway	O
is	O
associated	O
with	O
the	O
mTOR	O
downstream	I:C1515673
pathway	I:C1515673
mediated	O
by	O
YKL	O
-	I:C0528649
40	I:C0528649
protein	I:C0528649
,	O
and	O
the	O
combination	O
therapy	O
of	O
the	O
STAT3	O
inhibitor	O
and	O
rapamycin	O
could	O
be	O
worth	O
developing	O
as	O
a	O
novel	O
therapeutic	O
approach	I:C0087111
against	O
TMZ	B:C0076080
-	O
resistant	O
relapsed	O
gliomas	O
.	O

These	O
results	O
suggest	O
that	O
the	O
STAT3	O
pathway	O
is	O
associated	O
with	O
the	O
mTOR	O
downstream	I:C1515673
pathway	I:C1515673
mediated	O
by	O
YKL	O
-	I:C0528649
40	I:C0528649
protein	I:C0528649
,	O
and	O
the	O
combination	O
therapy	O
of	O
the	O
STAT3	O
inhibitor	O
and	O
rapamycin	O
could	O
be	O
worth	O
developing	O
as	O
a	O
novel	O
therapeutic	O
approach	I:C0087111
against	O
TMZ	O
-	O
resistant	B:C0013203
relapsed	O
gliomas	O
.	O

These	O
results	O
suggest	O
that	O
the	O
STAT3	O
pathway	O
is	O
associated	O
with	O
the	O
mTOR	O
downstream	I:C1515673
pathway	I:C1515673
mediated	O
by	O
YKL	O
-	I:C0528649
40	I:C0528649
protein	I:C0528649
,	O
and	O
the	O
combination	O
therapy	O
of	O
the	O
STAT3	O
inhibitor	O
and	O
rapamycin	O
could	O
be	O
worth	O
developing	O
as	O
a	O
novel	O
therapeutic	O
approach	I:C0087111
against	O
TMZ	O
-	O
resistant	O
relapsed	O
gliomas	B:C0017638
.	O

